Fusion Antibodies Ltd
Fusion Antibodies specializes in the rapid expression & purification of recombinant proteins and chimeric antibodies for the research, diagnostic and therapeutic markets. They offer a service based on their award winning high through-put FET™ (Fusion Expression Technology) platform. Broad experience and expertise has resulted in making over 500 of these proteins for a global customer base.
Their prime area of activity is in the area of antibody therapeutics where their research and development focus is the identification of over expressed proteins as targets in Oncology and Angiogenesis. Based on a combination therapy approach a pipeline of lead targets has been identified and the leading ones taken to pre clinical stage.
The company was founded in 2001 and was spun out of Queens University, Belfast, and having gained several awards is rapidly becoming one of Northern Irelands leading new companies in the BioPharma arena.
Fusion Antibodies specializes in the rapid expression & purification of recombinant proteins and chimeric antibodies for the research, diagnostic and therapeutic markets. They offer a service based on their award winning high through-put FET™ (Fusion Expression Technology) platform. Broad experience and expertise has resulted in making over 500 of these proteins for a global customer base.
Their prime area of activity is in the area of antibody therapeutics where their research and development focus is the identification of over expressed proteins as targets in Oncology and Angiogenesis. Based on a combination therapy approach a pipeline of lead targets has been identified and the leading ones taken to pre clinical stage.
The company was founded in 2001 and was spun out of Queens University, Belfast, and having gained several awards is rapidly becoming one of Northern Irelands leading new companies in the BioPharma arena.